Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b dose-ranging study of AZD8233 in adults with dyslipidemia
2020-000767-23Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2020
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in dyslipidemia comparing AZD8233 dose-ranging arms with Placebo arm (2 arms). Primary endpoint: Absolute change from baseline in log-transformed LDL-C in plasma. Started Sep 2020; status: completed.
02
Drugs
AZD8233
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on 2020-000767-23.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000767-23.